A genome-wide mapping and functional genomics approach to elucidating PRecOcious Coronary ARtery DISease (PROCARDIS)

Grunddaten zu diesem Projekt

Art des Projektes: EU-Projekt koordiniert außerhalb der Universität Münster
Laufzeit: 01.04.2007 - 30.09.2011

Beschreibung

The PROCARDIS programme, a genome-wide strategy to identify susceptibility loci in precocious CAD, was initiated in October 1998 as a collaboration between the universities of Oxford and Münster, the Karolinska Institute, the Mario Negri Institute, Oxagen (a biotechnology company), and AstraZeneca (the pharmaceutical company). This consortium received support from a Concerted Action award of the 5th Framework Programme for establishing the network and standardising of protocols for a family collection. In April 2007 it became a European Commission funded Framework 6 research consortium and is now a collaboration between 12 partners: the universities of Oxford and Münster; the Karolinska Institute; the Mario Negri Institute; Digilab BioVisioN GmbH (a biotechnology company); Centre National de Genotypage; Institut de Recerca del Hospital de la Santa Creu I Sant Pau; Università degli Studi di Milano; Clinical Gene Networks AB (a biotechnology company); CF consulting S.r.l. (Management consultants); Metabometrix Limited (a biotechnology company) and AstraZeneca (the pharmaceutical company).

Stichwörter: coronary artery disease; CAD